#Ireland #Dublin #Alkermes #Pathways Research #Neuroscience Awards

Alkermes Launches the 8th Annual Pathways Research Awards

Alkermes plc (Nasdaq: ALKS) has officially announced the opening of applications for its prestigious Alkermes Pathways Research Awards® program starting September 15, 2025. Now in its eighth year, this initiative aims to provide critical funding for innovative research in the field of neuroscience, particularly focusing on conditions such as schizophrenia and bipolar I disorder.

Grant Details

The competitive grant program will offer individual grants of up to $100,000 for each project proposed. By expanding its areas of interest, the program also aims to include research on sleep and circadian disturbances related to bipolar I disorder and schizophrenia. "Research in these areas is increasingly crucial as we look to understand the complexities of psychiatric disorders," explained Craig Hopkinson, M.D., Chief Medical Officer at Alkermes.

Eligibility Criteria

To be eligible, applicants must be early-career researchers, including M.D.s and Ph.D.s who have completed their initial academic appointment within the last five years or current post-doctoral fellows. These individuals need to be affiliated with recognized medical or research institutions within the United States. The evaluation of submitted proposals will be conducted by an independent committee of experts in relevant fields, including psychiatry, neurobiology, pharmacology, and sleep medicine.

This year marks a significant milestone, as the program has already distributed approximately $2.7 million in funding since its inception in 2018 to help advance neuroscience research among 27 investigators across the country.

Importance of Neuroscience Research

Neuroscience plays a vital role in understanding complex mental health conditions, and innovative research is necessary for advancing treatments. The Alkermes Pathways Research Awards program serves as a supportive platform for emerging researchers who are dedicated to tackling challenging questions in this critical field. The inclusion of sleep and circadian rhythm disturbances reflects a comprehensive approach to addressing the broader impacts of these psychiatric disorders and enhancing the quality of life for patients.

Application Process

Interested candidates can apply for the awards starting from Sept. 15, 2025, until Dec. 15, 2025. For full details regarding eligibility, the application process, and more, applicants are encouraged to visit www.PathwaysResearchAwards.com.

About Alkermes plc

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines in the field of neuroscience. With headquarters in Ireland and additional facilities in Massachusetts and Ohio, Alkermes works on a range of treatments for conditions like opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder. The company's ongoing commitment to research and development ensures that it remains at the forefront of advancements in neurological therapies.

For more information about Alkermes and its initiatives, visit www.alkermes.com. The Pathways Research Awards is a registered service mark of Alkermes, Inc.